The point prevalence estimates of anemia in patients with inflammatory bowel disease (IBD) range between 6% and 74%.
The variation is probably due to differences in the definition of anaemia and the study populations.
Dr Høivik and colleagues from Norway retrospectively determined the prevalence of anemia at diagnosis and at the 1-, 5- and 10-year follow-ups in patients with IBD from a prospectively followed, population-based inception cohort (the IBSEN Study).
The researchers compared the prevalence of anemia after a 10-year disease course with the prevalence of anemia in the background population, and assessed clinical factors associated with anemia at diagnosis and during follow-up.
The team evaluated newly diagnosed IBD patients in a population-based, prospective cohort.
Follow-up was performed at 1, 5 and 10 years.
|49% of patients with CD were anemic at diagnosis|
|Alimentary Pharmacology & Therapeutics|
All visits included clinical examinations and blood samples.
Anemia was defined according to the WHO.
The researchers included a total of 756 patients.
The team found that 49% with CD, and 20% of UC patients were anemic at diagnosis.
The proportion of patients with anaemia decreased during the disease course in all patients, except in women with CD.
After 10 years of disease, the relative risk for anemia was increased in all groups, except for women with UC.
The variables associated with anemia were generally unchanged during the disease course, and elevated CRP was the strongest predictor of risk.
Dr Høivik's team concludes, "Anemia was more common in CD than in UC."
"The prevalence of anemia decreased during the disease course."
"Women with CD were at high risk for anemia."
"Elevated CRP was independently associated with anemia."